Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Mizuho Maintains Buy on Dover, Lowers Price Target to $155

Mizuho Maintains Buy on Dover, Lowers Price Target to $155

Mizuho analyst Brett Linzey maintains Dover (NYSE:DOV) with a Buy and lowers the price target from $175 to $155.

byBenzinga Newsdesk

July 18, 2022

1 minute read

Mizuho analyst Brett Linzey maintains Dover (NYSE:DOV) with a Buy and lowers the price target from $175 to $155.

FDA Slaps Clinical Hold On Iovance Biotherapeutics’ Lung Cancer Study After Patient Death

By Vandana Singh

December 27, 11:21 AM

Wednesday, Iovance Biotherapeutics Inc (NASDAQ: IOVA) announced a clinical program update for LN-145 TIL therapy in non-

IOVA

Relief To Pfizer, Sanofi As US Dismisses Several Lawsuits Associated With Zantac

By Vandana Singh

December 7, 9:35 AM

U.S. District Judge Robin Rosenberg in Florida has dismissed about 50,000 claims associated with GSK Plc (NYSE:GSK), Pfizer Inc (NYSE:PFE), Sanofi SA (NASDAQ:SNY), and Boehringer Ingelheim, claiming…

GSK

Keybanc Maintains Overweight on CareTrust REIT, Raises Price Target to $22

By Benzinga Newsdesk

February 14, 5:30 AM

Keybanc analyst Austin Wurschmidt maintains CareTrust REIT (NYSE:CTRE) with a Overweight and raises the price target from $21 to $22.

CTRE

Analyst Ratings

Analyst Expectations For Intl Flavors & Fragrances’s Future

By Benzinga Insights

January 11, 4:01 PM

Ratings for Intl Flavors & Fragrances (NYSE:IFF) were provided by 7 analysts in the past three months, showcasing…

IFF

Mizuho Maintains Buy on Dover, Lowers Price Target to $155

Related Posts

FDA Slaps Clinical Hold On Iovance Biotherapeutics’ Lung Cancer Study After Patient Death

Relief To Pfizer, Sanofi As US Dismisses Several Lawsuits Associated With Zantac

Keybanc Maintains Overweight on CareTrust REIT, Raises Price Target to $22

Analyst Expectations For Intl Flavors & Fragrances’s Future